Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rani Therapeutics excels in 2022 with breakthrough drug delivery innovations

Rani Therapeutics made significant strides in 2022 with advancements in their RaniPill platform and promising Phase 1 results for RT-102, positioning the company for future growth.
Despite financial strength and successful partnerships, Rani faces challenges in maintaining clinical success rates, managing expenses, and navigating regulatory requirements.
Opportunities lie in expanding clinical trials, forging new partnerships, and innovating in drug delivery technologies to drive future growth and market expansion for Rani.

Rani Therapeutics excels in drug delivery innovation and clinical progress

Rani Therapeutics demonstrated strong performance in 2023 with positive Phase I results and successful oral delivery achievements, showcasing its innovative capabilities.
While facing challenges in negotiations and pipeline development, Rani has strengths in transformative technology and clinical expertise to navigate the competitive landscape.
With opportunities to expand drug delivery capabilities and strategic collaborations, Rani Therapeutics is poised for growth and advancement in the pharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company's Chief Executive Officer, Talat Imran, will present at two upcoming investor conferences in May:

Rani Therapeutics to Present at Upcoming Investor Conferences

SAN JOSE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company's Chief Executive Officer, Talat Imran, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. PT / 3:45 p.m. ET.

Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Rani Therapeutics Holdings, Inc. (RANI) Talat Imran on Q4 2021 Results - Earnings Call Transcript

- Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis -

Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022 after the close of market. Rani will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business update.

Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 29, 2022

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via RaniPill™ capsule.

Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis

SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quarter ended September 30, 2021, and provided a corporate update.

Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update

SAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Lyn Baranowski to its Board of Directors. Ms. Baranowski is a distinguished biotechnology executive with nearly two decades of experience.

Rani Therapeutics Appoints Lyn Baranowski to Board of Directors

A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.

This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company's Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET.

Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors' appointments -

Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

Applied Materials

Best Buy

Intuit

Medtronic

Toll Brothers

H&R Block

Kite Realty Group

Tenable Holdings Inc

The markets were higher across the board near midday, after a strong two-day rally opened the trading week.

Wednesday Afternoon Analyst Upgrades and Downgrades: Applied Materials, Best Buy, Intuit, Medtronic, Toll Brothers and More

RxSight

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTech company, went public in late July. Here's what BofA Securities has to say about the newly listed stocks.

Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA

SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics today announced the final closing of its initial public offering of 7,666,667 shares of its Class A common stock, which includes 1,000,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares, at a public offering price of $11.00 per share. The offering of 6,666,667 shares closed on August 3, 2021. The closing of the underwriters' partial exercise of 500,000 shares occurred on August 11, 2021, and the closing of the underwriters' exercise of their remaining option of 500,000 shares occurred on August 13, 2021. The gross proceeds to Rani from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $84.3 million. All of the shares in the offering were sold by Rani.

Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday.  According to S-1 filings, shares were estimated to price between $14 and $16 last week.

Rani Therapeutics' $73M IPO will fund upcoming clinical trials

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), a San Jose, California-based early stage biopharma, debuted Friday on the Nasdaq in its initial public offering. Rani Shares Trade Around IPO Price: Rani shares opened for trading at $11.26, above the IPO price of $11.

Rani Therapeutics Debuts On The Nasdaq: What You Should Know About The Biopharma

SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the pricing of its initial public offering of 6,666,667 shares of Class A common stock at a price to the public of $11.00 per share. The gross proceeds to Rani from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $73.3 million. In addition, Rani has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol “RANI” on July 30, 2021. The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.

Rani Therapeutics Announces Pricing of Initial Public Offering

Rani Therapeutics has filed to raise $100 million in an IPO. The firm is developing its RaniPill robotic drug delivery pill system for various drug treatments.

Rani Therapeutics Targets $100 Million IPO

News for Rani Therapeutics Holdings Stock (RANI)